Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT : vimarsana.com

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse

...

Related Keywords

Japan , United States , New Jersey , China , American , Hemophagocytic Lymphohistiocytosis , Surbhi Sidana , Birk Vanderwee , Ying Huang , Medicinal Devices Agency , European Commission , Linkedin , Oncologic Drugs Advisory Committee , Twitter , Legend Biotech Corporation , Drug Administration , Japan Ministry Of Health , Janssen Biotech Inc , Exchange Commission On , Johnson , American Cancer Society , Legend Biotech , B Cell Maturation Antigen , Chief Executive Officer , Drugs Advisory Committee , Assistant Professor , Marrow Transplantation , Cellular Therapy , Stanford University School , Senior Vice President , Global Manufacturing , Cytokine Release Syndrome , Macrophage Activation Syndrome , Recurrent Cytopenias , Secondary Malignancies , Increased Early Mortality , Hypersensitivity Reactions , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Risk Evaluation , Mitigation Strategy , Mediated Myelitis , Nerve Palsies , After Day , Maturet Cell , Janssen Biotech , Prescribing Information , Boxed Warning , Breakthrough Therapy Designation , Orphan Drug Designation , European Medicines Agency , Orphan Medicinal Products , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Study Comparing , Versus Pomalidomide , Participants With Relapsed , Lenalidomide Refractory Multiple Myeloma , Accessed March , Statistics About Multiple Myeloma , Markets ,